Market access webinar

Understanding the concept of early scientific advice and its purpose across HTA markets

Fill in your details to watch this webinar

We respect your privacy. Cookie policy.

Wednesday 13 July 2022: 08:00 PDT, 11:00 EDT, 16:00 BST 

Thursday 14 July 2022: 09:00 BST, 16:00 SST 

Uncertainty and inappropriate trial design are the main reasons why medicines fare badly in health technology assessments (HTA). HTA scientific advice recommendations can identify key payer evidence requirements and areas of uncertainty, and when implemented result in stronger HTA submissions. 

This webinar explores the benefits, processes, and key considerations from an industry perspective of HTA scientific advice in the key HTA markets.

Discussion points

  • Discover why industry is increasingly utilizing HTA scientific advice as part of early development planning. 
  • Examine the considerations for and feasibility of obtaining HTA scientific advice across key markets. 
  • Explore the HTA challenges that contribute to the prioritization of candidate assets for HTA scientific advice and the framing of key questions. 

Learning aims

  • Understand the principles and benefits of HTA scientific advice, as well as what it can or cannot achieve. 
  • Learn best practice for prioritization and feasibility assessment of assets for HTA scientific advice in key markets. 
  • Gain practical recommendations for preparation and implementation of HTA scientific advice meetings that will increase the value of your consultation. 

Presenters:

     

Samara brings nearly 20 years’ experience in health economics and market access, building and communicating the value of products to national and local access stakeholders at UK, EU, and global level. 

Samara leads on a wide variety of projects at PRMA Consulting, including value communication, primary research with payers and clinicians, and PRMA Healthcheck®, across a range of disease areas. Her experience from previous roles covers HTA submissions, development of regional and local payer materials and tools, leading the development of global payer value messages, GVDs, economic models and evidence synthesis, as well inputting to clinical development from a health economics and payer evidence needs perspective. 

She has previously worked across several disease areas, including immunology bone, diabetes, CVD, respiratory, HIV, and oncology. 

 

  

Sanjeev has a number of years of market access experience. He has held senior leadership roles within the pharmaceutical industry and recently led launch excellence activities in cellular therapy covering all aspects from access to operational implementation. 

His experience spans translational medicine, health systems, and commercialization in drug development and diagnostics. Sanjeev has a passion for cell and gene therapy, companion diagnostics, clinical pathways, real-world data, and cancer systems. 

He has expertise across a number of disease areas with specialism in oncology/hematology. 

Duration: 20 minutes.

Ideal viewing: This webinar is for those in global and regional roles who want to explore scientific advice processes, feasibility, and implementation, and how to prioritize assets for consultation.  

Broadcast: 2022 

Previous webinars

Increase your influence in early pipeline planning: why earlier value assessment of your assets through a payer lens makes a difference.

Read more >

How to demonstrate the value of vaccines in line with global NITAG and HTA requirements

Read more >

Market access for biotechnology

Read more >

How to build an optimized GVD to populate local HTA/payer templates

Read more >

Recommendations for driving your journey to digital excellence

Read more >

The PRMA Healthcheck®: the future of market access in Asia-Pacific

Read more >

Transform your market access in Asia-Pacific

Read more >

PRMA Healthcheck® for assets in early stages of clinical development

Read more >

The evolution of the PRMA Healthcheck® for US payer archetypes

Read more >

Navigating the updated 2020 ICER value assessment framework

Read more >

Accelerate the time to patient access with the PRMA Navigator®

Read more >

EUnetHTA joint clinical assessments: where have we come from and where are we going?

Read more >

Future proofing for the 2020s market access trends

Read more >

Managed entry agreements: lessons from EU5

Read more >

CAR-T therapy: the future begins to take shape

Read more >

Indication-specific pricing: the obvious solution

Read more >

Payer perspectives on cell and gene therapies: opportunities and challenges

Read more >

Market access considerations for CAR-Ts: insights from ASH

Read more >

Patient-centricity: shaping value generation for HTA and market access

Read more >

Market access for PD-1 inhibitors: where are we now?

Read more >

Does 1+1 always equal 2? Valuing combinations

Read more >

Clarity or confusion: the role of value frameworks in oncology

Read more >